Related Experiment Video

Updated: Dec 13, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K

Polydatin executes anticancer effects against glioblastoma multiforme by inhibiting the

Yaodong Chen1, Jiamei Niu2, Lulu Li3

  • 1Department of Ultrasonic Imaging, First Hospital of Shanxi Medical University, Taiyuan 030001, China; Department of Abdominal Ultrasonography, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.

Life Sciences
|August 5, 2020
PubMed
Abstract

Insights

Polydatin (PD) inhibits glioblastoma multiforme (GBM) growth by reducing cell proliferation, migration, and invasion while promoting apoptosis. This anticancer effect is linked to the inhibition of the EGFR-AKT/ERK1/2/STAT3-SOX2/Snail signaling pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis.
  • Current chemotherapies have limited efficacy against GBM.
  • Polydatin (PD), a natural compound, shows potential anticancer properties but its effect on GBM is unknown.

Purpose of the Study:

  • To investigate the anti-GBM effects of Polydatin (PD).
  • To elucidate the molecular mechanisms underlying PD's action in GBM.

Main Methods:

  • In vitro assays (MTT, colony formation, flow cytometry, wound-healing, Transwell) assessed GBM cell proliferation, apoptosis, migration, and invasion.
  • In vivo studies utilized a subcutaneous tumor model in nude mice.
  • Western blot, immunofluorescence, and immunohistochemistry analyzed molecular pathways.

Main Results:

  • PD significantly repressed GBM cell proliferation, migration, invasion, and stemness.
  • PD induced apoptosis in GBM cells.
  • PD's cytotoxicity was associated with the inhibition of the EGFR-AKT/ERK1/2/STAT3-SOX2/Snail signaling pathway.

Conclusions:

  • Polydatin exhibits significant anti-GBM activity.
  • PD inhibits GBM progression by targeting key components of the EGFR-AKT/ERK1/2/STAT3-SOX2/Snail pathway.
  • PD represents a potential therapeutic agent for glioblastoma multiforme.
Keywords:
EGFR-AKT/ ERK1/2/STAT3-SOX2/Snail signaling pathwayEpithelial-mesenchymal transitionGlioblastoma multiformeModularityPolydatin

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.3K